RNAi-mediated c-Rel silencing leads to apoptosis of B cell tumor cells and suppresses antigenic immune response in vivo

PLoS ONE

Volumn 4, Issue 4, 2009, Pages

  Tian, Wenzhi ^a   Liou, Hsiou Chi ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; RETROVIRUS VECTOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR REL; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGENICITY; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; MOUSE; NONHUMAN; RNA INTERFERENCE; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BIOSYNTHESIS; CELL LINE; CELL STRAIN 3T3; EXPERIMENTAL NEOPLASM; GENETICS; IMMUNOLOGY; NUCLEOTIDE SEQUENCE; PATHOLOGY;

ANIMALS; ANTIGENS, NEOPLASM; APOPTOSIS; B-LYMPHOCYTES; BASE SEQUENCE; CELL LINE; GENE SILENCING; MICE; NEOPLASMS, EXPERIMENTAL; NIH 3T3 CELLS; PROTO-ONCOGENE PROTEINS C-REL; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 64549141966     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005028     Document Type: Article

References (107)

1. John M, Constien R, Akinc A, Goldberg M, Moon YA, et al. (2007) Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature 449: 745-747.
2. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J (2007) Interfering with disease: a progress report on siRNA-based therapeutics. Nature reviews 6: 443-453.
3. Hoffmann A, Baltimore D (2006) Circuitry of nuclear factor kappaB signaling. Immunol Rev 210: 171-186.
4. Hayden MS, Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell 132: 344-362.
5. Karin M (2008) The IkappaB kinase - a bridge between inflammation and cancer. Cell research 18: 334-342.
6. Gilmore TD (2006) Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25: 6680-6684.
7. Fan Y, Dutta J, Gupta N, Fan G, Gelinas C (2008) Regulation of programmed cell death by NF-kappaB and its role in tumorigenesis and therapy. Adv Exp Med Biol 615: 223-250.
8. Liou HC, Hsia CY (2003) Distinctions between c-Rel and other NF-kappaB proteins in immunity and disease. Bioessays 25: 767-780.
9. Chang CC, Zhang J, Lombardi L, Neri A, Dalla-Favera R (1994) Mechanism of expression and role in transcriptional control of the proto-oncogene NFKB-2/LYT-10. Oncogene 9: 923-933.
10. Sanjabi S, Williams KJ, Saccani S, Zhou L, Hoffmann A, et al. (2005) A c-Rel subdomain responsible for enhanced DNA-binding affinity and selective gene activation. Genes Dev 19: 2138-2151.
11. Hoffmann A, Natoli G, Ghosh G (2006) Transcriptional regulation via the NF-kappaB signaling module. Oncogene 25: 6706-6716.
12. Perkins ND, Gilmore TD (2006) Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ 13: 759-772.
13. Liou HC, Sha WC, Scott ML, Baltimore D (1994) Sequential induction of NF-kappa B/Rel family proteins during B-cell terminal differentiation. Mol Cell Biol 14: 5349-5359.
14. Miyamoto S, Verma IM (1994) Qualitative changes in the subunit composition of kappa-B binding complexes during murine B-cell differentiation. Proc Natl Acad Sci USA 91: 5056-5060.
15. Bottero V, Withoff S, Verma IM (2006) NF-kappaB and the regulation of hematopoiesis. Cell Death Differ 13: 785-797.
16. Weih F, Carrasco D, Bravo R (1994) Constitutive and inducible Rel/ NF-kappa B activities in mouse thymus and spleen. Oncogene 9: 3289-3297.
17. Donovan CE, Mark DA, He HZ, Liou HC, Kobzik L, et al. (1999) NF-kappa B/ Rel transcription factors: c-Rel promotes airway hyperresponsiveness and allergic pulmonary inflammation. J Immunol 163: 6827-6833.
18. Lamhamedi-Cherradi SE, Zheng S, Hilliard BA, Xu L, Sun J, et al. (2003) Transcriptional regulation of type I diabetes by NF-kappa B. J Immunol 171: 4886-4892.
19. Hilliard BA, Mason N, Xu L, Sun J, Lamhamedi-Cherradi SE, et al. (2002) Critical roles of c-Rel in autoimmune inflammation and helper T cell differentiation. J Clin Invest 110: 843-850.
20. Finn PW, He H, Ma C, Mueller T, Stone JR, et al. (2002) Molecular profiling of the role of the NF-kappaB family of transcription factors during alloimmunity. J Leukoc Biol 72: 1054-1062.
21. Yang H, Thomas D, Boffa DJ, Ding R, Li B, et al. (2002) Enforced c-REL deficiency prolongs survival of islet allografts1. Transplantation 74: 291-298.
22. Campbell IK, Gerondakis S, O'Donnell K, Wicks IP (2000) Distinct roles for the NF-kappaB1 (p50) and c-Rel transcription factors in inflammatory arthritis. J Clin Invest 105: 1799-1806.
23. Caamano JH, Rizzo CA, Durham SK, Barton DS, Raventos-Suarez C, et al. (1998) Nuclear factor (NF)-kappa B2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses. J Exp Med 187: 185-196.
24. Franzoso G, Carlson L, Poljak L, Shores EW, Epstein S, et al. (1998) Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J Exp Med 187: 147-159.
25. Weih F, Carrasco D, Durham SK, Barton DS, Rizzo CA, et al. (1995) Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kB/Rel family. Cell 80: 331-340.
26. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D (1995) Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 376: 167-170.
27. Beg AA, Baltimore D (1996) An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 274: 782-784.
28. Gilmore TD, Kalaitzidis D, Liang MC, Starczynowski DT (2004) The c-Rel transcription factor and B-cell proliferation: a deal with the devil. Oncogene 23: 2275-2286.
29. Gilmore TD, Cormier C, Jean-Jacques J, Gapuzan ME (2001) Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel. Oncogene 20: 7098-7103.
30. Gilmore TD (1992) Role of rel family genes in normal and malignant lymphoid cell growth. Cancer Surv 15: 69-87.
31. Fan Y, Rayet B, Gelinas C (2004) Divergent C-terminal transactivation domains of Rel/NF-kappa B proteins are critical determinants of their oncogenic potential in lymphocytes. Oncogene 23: 1030-1042.
32. Rayet B, Gelinas C (1999) Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18: 6938-6947.
33. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, et al. (2002) NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277: 16639-16647.
34. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, et al. (2007) Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12: 131-144.
35. Gilmore TD (2007) Multiple myeloma: lusting for NF-kappaB. Cancer Cell 12: 95-97.
36. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, et al. (2007) Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115-130.
37. Bernal A, Pastore RD, Asgary Z, Keller SA, Cesarman E, et al. (2001) Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood 98: 3050-3057.
38. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ (2000) Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 164: 2200-2206.
39. Romano MF, Lamberti A, Tassone P, Alfinito F, Costantini S, et al. (1998) Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood 92: 990-995.
40. Chiorazzi N (2007) Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells. Best Pract Res Clin Haematol 20: 399-413.
41. Davis RE, Brown KD, Siebenlist U, Staudt LM (2001) Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194: 1861-1874.
42. Houldsworth J, Olshen AB, Cattoretti G, Donnelly GB, Teruya-Feldstein J, et al. (2004) Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. Blood 103: 1862-1868.
43. Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, et al. (2005) Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 11: 28-40.
44. Ngo VN, Davis RE, Lamy L, Yu X, Zhao H, et al. (2006) A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441: 106-110.
45. Lam LT, Wright G, Davis RE, Lenz G, Farinha P, et al. (2008) Cooperative signaling through the STAT3 and NF-{kappa}B pathways in subtypes of diffuse large B cell lymphoma. Blood.
46. Starczynowski DT, Reynolds JG, Gilmore TD (2003) Deletion of either C-terminal transactivation subdomain enhances the in vitro transforming activity of human transcription factor REL in chicken spleen cells. Oncogene 22: 6928-6936.
47. Starczynowski DT, Reynolds JG, Gilmore TD (2005) Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability. Oncogene 24: 7355-7368.
48. Kontgen F, Grumont RJ, Strasser A, Metcalf D, Li R, et al. (1995) Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev 9: 1965-1977.
49. Grossmann M, Nakamura Y, Grumont R, Gerondakis S (1999) New insights into the roles of ReL/NF-kappa B transcription factors in immune function, hemopoiesis and human disease. Int J Biochem Cell Biol 31: 1209-1219.
50. Liou HC, Jin Z, Tumang J, Andjelic S, Smith KA, et al. (1999) c-Rel is crucial for lymphocyte proliferation but dispensable for T cell effector function. Int Immunol 11: 361-371.
51. Banerjee D, Liou HC, Sen R (2005) c-Rel-dependent priming of naive T cells by inflammatory cytokines. Immunity 23: 445-458.
52. Harling-McNabb L, Deliyannis G, Jackson DC, Gerondakis S, Grigoriadis G, et al. (1999) Mice lacking the transcription factor subunit Rel can clear an influenza infection and have functional anti-viral cytotoxic T cells but do not develop an optimal antibody response. Int Immunol 11: 1431-1439.
53. Mason N, Aliberti J, Caamano JC, Liou HC, Hunter CA (2002) Cutting edge: identification of c-Rel-dependent and -independent pathways of IL-12 production during infectious and inflammatory stimuli. J Immunol 168: 2590-2594.
54. Mason NJ, Liou HC, Hunter CA (2004) T cell-intrinsic expression of c-Rel regulates Th1 cell responses essential for resistance to Toxoplasma gondii. J Immunol 172: 3704-3711.
55. Gerondakis S, Grumont R, Rourke I, Grossmann M (1998) The regulation and roles of Rel/NF-kappa B transcription factors during lymphocyte activation. Curr Opin Immunol 10: 353-359.
56. Grumont RJ, Rourke IJ, Gerondakis S (1999) Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev 13: 400-411.
57. Andjelic S, Hsia C, Suzuki H, Kadowaki T, Koyasu S, et al. (2000) Phosphatidylinositol 3-kinase and NF-kappa B/Rel are at the divergence of CD40-mediated proliferation and survival pathways. J Immunol 165: 3860-3867.
58. Huang X, Di Liberto M, Cunningham AF, Kang L, Cheng S, et al. (2004) Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1. Proc Natl Acad Sci U S A 101: 17789-17794.
59. Hsia CY, Cheng S, Owyang AM, Dowdy SF, Liou HC (2002) c-Rel regulation of the cell cycle in primary mouse B lymphocytes. Int Immunol 14: 905-916.
60. Cheng S, Hsia CY, Leone G, Liou HC (2003) Cyclin E and Bcl-xL cooperatively induce cell cycle progression in c-Rel2/2 B cells. Oncogene 22: 8472-8486.
61. Tumang JR, Owyang A, Andjelic S, Jin Z, Hardy RR, et al. (1998) C-Rel is essential for B lymphocyte survival and cell cycle progression. Eur J Immunol 28: 4299-4312.
62. Owyang AM, Tumang JR, Schram BR, Hsia CY, Behrens TW, et al. (2001) c-Rel is required for the protection of B cells from antigen receptor-mediated, but not Fas-mediated, apoptosis. J Immunol 167: 4948-4956.
63. Weinmann AS, Mitchell DM, Sanjabi S, Bradley MN, Hoffmann A, et al. (2001) Nucleosome remodeling at the IL-12 p40 promoter is a TLR-dependent, Rel- independent event. Nat Immunol 2: 51-57.
64. Tumang JR, Hsia CY, Tian W, Bromberg JF, Liou HC (2002) IL-6 rescues the hyporesponsiveness of c-Rel deficient B cells independent of Bcl-xL, Mcl-1, and Bcl-2. Cell Immunol 217: 47-57.
65. Carmody RJ, Ruan Q, Liou HC, Chen YH (2007) Essential roles of c-Rel in TLR-induced IL-23 p19 gene expression in dendritic cells. J Immunol 178: 186-191.
66. Grumont RJ, Gerondakis S (2000) Rel induces interferon regulatory factor 4 (IRF-4) expression in lymphocytes: modulation of interferon-regulated gene expression by rel/nuclear factor kappaB. J Exp Med 191: 1281-1292.
67. Grumont R, Hochrein H, O'Keeffe M, Gugasyan R, White C, et al. (2001) c-Rel regulates interleukin 12 p70 expression in CD8(+) dendritic cells by specifically inducing p35 gene transcription. J Exp Med 194: 1021-1032.
68. Rao S, Gerondakis S, Woltring D, Shannon MF (2003) c-Rel is required for chromatin remodeling across the IL-2 gene promoter. J Immunol 170: 3724-3731.
69. Birmingham A, Anderson E, Sullivan K, Reynolds A, Boese Q, et al. (2007) A protocol for designing siRNAs with high functionality and specificity. Nature protocols 2: 2068-2078.
70. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, et al. (2004) Rational siRNA design for RNA interference. Nat Biotechnol 22: 326-330.
71. Mittal V (2004) Improving the efficiency of RNA interference in mammals. Nat Rev Genet 5: 355-365.
72. Naito Y, Yamada T, Ui-Tei K, Morishita S, Saigo K (2004) siDirect: highly effective, target-specific siRNA design software for mammalian RNA interference. Nucleic Acids Res 32: W124-129.
73. Tian W, Feng B, Liou HC (2005) Silencing OCILRP2 leads to intrinsic defects in T cells in response to antigenic stimulation. Cell Immunol 235: 72-84.
74. Tian W, Nunez R, Cheng S, Ding Y, Tumang J, et al. (2005) C-type lectin OCILRP2/Clr-g and its ligand NKRP1f costimulate T cell proliferation and IL-2 production. Cell Immunol 234: 39-53.
75. Feng B, Cheng S, Pear WS, Liou HC (2004) NF-kB inhibitor blocks B cell development at two checkpoints. Med Immunol 3: 1.
76. Lee H, Arsura M, Wu M, Duyao M, Buckler AJ, et al. (1995) Role of Rel-related factors in control of c-myc gene transcription in receptor-mediated apoptosis of the murine B cell WEHI 231 line. J Exp Med 181: 1169-1177.
77. Fang W, Rivard JJ, Ganser JA, Le Bien TW, Nath KA, et al. (1995) Bcl-xL rescues WEHI 231 B lymphocytes from oxidant-mediated death following diverse apoptotic stimuli. J Immunol 155: 66-75.
78. Wu M, Arsura M, Bellas RE, FitzGerald MJ, Lee H, et al. (1996) Inhibition of c-myc expression induces apoptosis of WEHI 231 murine B cells. Mol Cell Biol 16: 5015-5025.
79. Schauer SL, Wang Z, Sonenshein GE, Rothstein TL (1996) Maintenance of nuclear factor-kappa B/Rel and c-myc expression during CD40 ligand rescue of WEHI 231 early B cells from receptor-mediated apoptosis through modulation of I kappa B proteins. J Immunol 157: 81-86.
80. Siebelt F, Berberich I, Shu G, Serfling E, Clark EA (1997) Role for CD40-mediated activation of c-Rel and maintenance of c-myc RNA levels in mitigating anti-IgM-induced growth arrest. Cell Immunol 181: 13-22.
81. Donjerkovic D, Mueller CM, Scott DW (2000) Steroid- and retinoid-mediated growth arrest and apoptosis in WEHI-231 cells: role of NF-kappaB, c-Myc and CKI p27(Kip1). Eur J Immunol 30: 1154-1161.
82. Banerji L, Glassford J, Lea NC, Thomas NS, Klaus GG, et al. (2001) BCR signals target p27(Kip1) and cyclin D2 via the PI3-K signalling pathway to mediate cell cycle arrest and apoptosis of WEHI 231 B cells. Oncogene 20: 7352-7367.
83. Mineva ND, Rothstein TL, Meyers JA, Lerner A, Sonenshein GE (2007) CD40 ligand-mediated activation of the de novo RelB NF-kappaB synthesis pathway in transformed B cells promotes rescue from apoptosis. J Biol Chem 282: 17475-17485.
84. O'Connor S, Shumway SD, Amanna IJ, Hayes CE, Miyamoto S (2004) Regulation of constitutive p50/c-Rel activity via proteasome inhibitor-resistant IkappaBalpha degradation in B cells. Mol Cell Biol 24: 4895-4908.
85. Andjelic S, Hsia C, Suzuki H, Kadowaki T, Koyasu S, et al. (2000) Phosphatidylinositol 3-kinase and NF-kappa B/Rel are at the divergence of CD40-mediated proliferation and survival pathways. J Immunol 165: 3860-3867.
86. Andjelic S, Liou HC (1998) Antigen receptor-induced B lymphocyte apoptosis mediated via a protease of the caspase family. Eur J Immunol 28: 570-581.
87. Wu M, Yang W, Bellas RE, Schauer SL, FitzGerald MJ, et al. (1997) c-myc promotes survival of WEHI 231 B lymphoma cells from apoptosis. Curr Top Microbiol Immunol 224: 91-101.
88. Wu M, Lee H, Bellas RE, Schauer SL, Arsura M, et al. (1996) Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells. Embo J 15: 4682-4690.
89. Grumont RJ, Rourke IJ, O'Reilly LA, Strasser A, Miyake K, et al. (1998) B lymphocytes differentially use the Rel and nuclear factor kappaB1 (NF-kappaB1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells. J Exp Med 187: 663-674.
90. Wang W, Tam WF, Hughes CC, Rath S, Sen R (1997) c-Rel is a target of pentoxifylline-mediated inhibition of T lymphocyte activation. Immunity 6: 165-174.
91. Venkataraman L, Wang W, Sen R (1996) Differential regulation of c-Rel translocation in activated B and T cells. J Immunol 157: 1149-1155.
92. Venkataraman L, Burakoff SJ, Sen R (1995) FK506 inhibits antigen receptor-mediated induction of c-rel in B and T lymphoid cells. J Exp Med 181: 1091-1099.
93. Sanjabi S, Hoffmann A, Liou HC, Baltimore D, Smale ST (2000) Selective requirement for c-Rel during IL-12 P40 gene induction in macrophages. Proc Natl Acad Sci U S A 97: 12705-12710.
94. Finn PW, He H, Ma C, Mueller T, Stone JR, et al. (2002) Molecular profiling of the role of the NF-kappaB family of transcription factors during alloimmunity. J Leukoc Biol 72: 1054-1062.
95. Strasser A, Grumont RJ, Stanley ML, Gerondakis S (1999) The transcriptional regulator Rel is essential for antigen receptor-mediated stimulation of mature T cells but dispensable for positive and negative selection of thymocytes and T cell apoptosis. Eur J Immunol 29: 928-935.
96. Feng B, Cheng S, Hsia CY, King LB, Monroe JG, et al. (2004) NF-kappaB inducible genes BCL-X and cyclin E promote immature B-cell proliferation and survival. Cell Immunol 232: 9-20.
97. Chen C, Edelstein LC, Gelinas C (2000) The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 20: 2687-2695.
98. Chen X, Kandasamy K, Srivastava RK (2003) Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res 63: 1059-1066.
99. Lee H, Wu M, La Rosa FA, Duyao MP, Buckler AJ, et al. (1995) Role of the Rel-family of transcription factors in the regulation of c-myc gene transcription and apoptosis of WEHI 231 murine B-cells. Curr Top Microbiol Immunol 194: 247-255.
100. Grumont RJ, Strasser A, Gerondakis S (2002) B cell growth is controlled by phosphatidylinosotol 3-kinase-dependent induction of Rel/NF-kappaB regulated c-myc transcription. Mol Cell 10: 1283-1294.
101. Li ZW, Chu W, Hu Y, Delhase M, Deerinck T, et al. (1999) The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med 189: 1839-1845.
102. Henke E, Perk J, Vider J, de Candia P, Chin Y, et al. (2008) Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. Nat Biotechnol 26: 91-100.
103. Akinc A, Zumbuehl A, Goldberg M, Leshchiner ES, Busini V, et al. (2008) A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 26: 561-569.
104. Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, et al. (2005) Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23: 709-717.
105. Wolfrum C, Shi S, Jayaprakash KN, Jayaraman M, Wang G, et al. (2007) Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 25: 1149-1157.
106. Kumar P, Wu H, McBride JL, Jung KE, Kim MH, et al. (2007) Transvascular delivery of small interfering RNA to the central nervous system. Nature 448: 39-43.
107. Pear WS, Nolan GP, Scott ML, Baltimore D (1993) Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 90: 8392-8396.